BOSTON– AI Proteins, Inc., a pioneering company utilizing artificial intelligence to design novel miniprotein therapeutics, today announced the appointment of Dr. Philip E. Brandish, PhD as Chief Development Officer (CDO). Dr. Brandish brings vast leadership experience in the life sciences sector, with a proven track record of discovery and development of novel therapeutics, leading program teams from target validation and candidate selection through IND and into clinical proof-of-concept.
“Phil is a crucial addition to our leadership team, bringing extensive experience developing drugs, driving collaborations and leading high-performing teams,” said Dr. Chris Bahl, President, CEO and Founder of AI Proteins. “Phil joins us at an exciting time, as our platform is churning out lead molecules that address highly-demanding therapeutic criteria at breakneck speed. Phil will lead our rigorous target selection and prioritization process in addition to our development efforts.”
Dr. Brandish joins AI Proteins from Bicycle Therapeutics where he most recently served as Senior Vice President with responsibility for the internal preclinical pipeline and US-based research scientists. Prior to Bicycle, Dr. Brandish was a veteran leader at Merck & Co, Inc. where he oversaw early development of pre-clinical and clinical-stage Oncology programs.
“I am thrilled and privileged to be joining forces with Chris and the extraordinary team of scientists at AI Proteins,” said Dr. Brandish. “The AI-based miniprotein discovery platform that they have created and reduced to practice presents an unparalleled opportunity. That is, to create impactful new therapeutics that precisely meet the design goals dictated by the disease biology and by what patients need.”
